Despite major advances in organic synthesis predominantly over the past hundred years or so, *asymmetric synthesis of chiral organic compounds including the great majority of bioactive compounds*, *such as amino acids and their oligomers and polymers*, *i.e.*, *peptides*, *has remained as one of the "last bastions" to be conquered*.

As alarmed by the unfortunate incident of a tranquilizer, Thalidomide,^[@r01])^ any bioactive organic compounds of biological and medicinal concerns must be prepared in the "**YESES**" manners, satisfying all of the following requirements including (i) high **Y**ields, (ii) high **E**fficiency to be reflected most significantly in the number of synthetic steps, (iii) high **S**electivity leading to high purity as high as required, (iv) **E**conomy mandating highly catalytic processes, and (v) last but not least, unfailing **S**afety, which is often closely linked with **S**electivity.

As is well known, discovery of the existence of enantiomeric isomers of organic compounds as well as their isolation as enantiomerically pure isomers with the use of tweezers under microscope were performed for the preparation of enantiomerically pure D-(−)- and L-(+)-tartaric acids as early as the mid-nineteenth century by L. Pasteur.^[@r02],[@r03])^

Approximately half a century later, the first Nobel Prize in Chemistry was awarded to J. H. van't Hoff in 1901.^[@r04])^ Among his various contributions pertaining to the relationships between configurations of C atoms and various physical and chemical properties including chirality, optical activity, and so on, he predicted that α,ω-di-, tri-, or tetrasubstituted cumulenes, *i.e.*, ![](pjab-91-369-i001.jpg), can be chiral and optically active in cases where the number of cumulating C=C, *i.e.* *n*, is odd and 3 or higher.^[@r05],[@r06])^

The second Nobel Prize in Chemistry in 1902 recognized E. Fischer's astounding achievements in the syntheses of various complex organic compounds including a number of mono- and oligosaccharides.^[@r07],[@r08])^ As monumental as his *diastereoselective* syntheses were, additionally and more critically needed were *enantioselective* syntheses of a wide range of chiral organic compounds, as complementary, supplementary, and hopefully superior routes to the desired chiral organic compounds. This, however, proved to be a highly challenging goal.

Historically, yet another fundamentally significant advance in the asymmetric synthesis of chiral organic compounds was made about half a century later, when K. Ziegler^[@r09],[@r10])^ of Germany and G. Natta^[@r11])^ of Italy developed their isotactic polymerization of ethylene, propylene, and other alkenes, which led to their Nobel Prizes won in 1963. As both scientifically and industrially significant as these developments have been, these alkene polymerization reactions dealt only with "tacticity", *i.e.*, relative stereochemistry rather than absolute stereochemistry.

Major revolutionary discoveries and developments along the latter line have been made mostly since the 1970s. Concurrently, a group of industrial researchers at Monsanto, led by W. S. Knowles,^[@r12],[@r13])^ and R. Noyori in Japan^[@r14],[@r15])^ reported highly catalytic and selective hydrogenation of alkenes, especially allyllically heterofunctional alkenes. Some promisingly leads reported by H. Kagan in France^[@r16])^ are also noteworthy. K. B. Sharpless^[@r17],[@r18])^ with one of his associates T. Katsuki reported asymmetric epoxidation of allylic alcohols in 1980.^[@r17])^ It should be clearly noted, however, that none of these enantioselective reactions directly involves C--C bond formation.

Discovery and application of Zr-catalyzed methylalumination of alkynes (ZMA)
============================================================================

In 1978, we discovered **Z**r-catalyzed **m**ethylalumination of **a**lkynes (ZMA)^[@r19]--[@r21])^ and tentatively proposed its mechanism as shown in Scheme [1](#sc01){ref-type="scheme"}. The synthetic scope and utility of the ZMA reaction may be most vividly appreciated by noting numerous examples of its application to natural product syntheses. About 150 natural product syntheses were listed in our previous review.^[@r22])^ Since then, its use in more than 60 natural product syntheses has been reported. Some representative examples are listed in Table [1](#tbl01){ref-type="table"} and Scheme [2](#sc02){ref-type="scheme"}.

Discovery of Zr-catalyzed asymmetric carboalumination of alkenes (ZACA)
=======================================================================

Encouraged by the discovery and development of the alkyne carboalumination reaction catalyzed by Cp~2~ZrCl~2~ (ZMA),^[@r19]--[@r21])^ our search for a more highly coveted alkene-version of the reaction was resumed in the early 1980s. If only the alkyne carboalumination could be modified for discovering the corresponding alkene carboalumination reaction with suitable chiral zirconocene derivatives, we would most likely discover a catalytic and enantioselective C--C bond-forming reaction, namely the ZACA (**Z**r-catalyzed **a**symmetric **c**arboalumination of **a**lkenes). We believed that our notion of promoting carbometalation of alkenes with "super-acidic" bimetallic reagents consisting of alkylalanes and 16-electron zirconocene derivatives^[@r21],[@r72])^ should provide us with desirable alkene carbometalation reactions. This, however, proved to be more challenging and time-consuming endeavor than anticipated. In the end, however, our basic assumptions proved to be reasonable, and what may be termed a "one-step Ziegler-Natta alkene polymerization reaction" was almost single-handedly discovered in 1995 by Dr. D. Y. Kondakov (Scheme [3](#sc03){ref-type="scheme"}).^[@r73]--[@r75])^

All of the available data and observations are consistent with our notions and belief that the reaction involves Al-promoted carbozirconation of alkenes in accord with widely accepted mechanistic insights in the area of the Ziegler-Natta alkene polymerization. The observed high enantioselectivity seems to strongly favor Al-promoted carbozirconation mechanism as opposed to Zr-promoted carboalumination mechanism. Why did the discovery of the alkene ZACA reaction take such a long time, *i.e.*, 17 years, after the discovery of the Zr-catalyzed carboalumination of alkynes? Arguably, carbometalation is fundamentally less facile than hydrometalation for various reasons which are not discussed here except to point out more stringent steric requirements stemming from shear bulk and more highly directional properties of C relative to H, just to mention a few.

We painfully learned that the reaction of 1-alkenes with alkylalanes in the presence of zirconocene derivatives could undergo a few other competitive side reactions in addition to the desired single-stage carbometalation shown in the green frame of Scheme [4](#sc04){ref-type="scheme"}, of which (i) H-transfer hydrometalation,^[@r76])^ (ii) the Kaminsky version of Ziegler-Natta polymerization,^[@r77])^ (iii) bimetallic cyclic carbometalation,^[@r74])^ and (iv) monometallic cyclic carbometalation^[@r78])^ are representative. For favorable results, all of the side reactions shown in the red frame of Scheme [4](#sc04){ref-type="scheme"} must be effectively suppressed.

Having learned about these major pitfalls, the remaining major task was to find some satisfactory chiral zirconocene catalysts with sufficiently, but not excessively, bulky ligands to suppress unwanted side reactions, while promoting the desired alkene carbometalation. In this respect, no systematic catalyst optimization involving catalyst design has as yet been made. Instead, a dozen to fifteen known chiral zirconocene complexes were initially screened. Widely used (EBI)ZrCl~2~^[@r79])^ and its partially hydrogenated derivatives^[@r80])^ were less effective. The most effective among those tested is Erker's (NMI)~2~ZrCl~2~.^[@r81])^ Although methylalumination is singularly important from the viewpoint of the synthesis of natural products, it is ironically the uniquely unfavorable case where the *ee* figures are around 75%, as compared with ethylalumination and higher alkylalumination which proceeds in 90--95% *ee*. An attractive alternative has been developed by taking advantage of high enantioselectivity observed in ethylalumination and higher alkylalumination.^[@r82],[@r83])^ There are currently three Zr-catalyzed asymmetric carboalumination protocols that can be used for the synthesis of methyl-branched 1-alkanols (Scheme [5](#sc05){ref-type="scheme"}).^[@r82],[@r83])^

Development and application of ZACA reaction
============================================

Despite some room for improvement, especially (i) improvement of the enantioselectivity of carboalumination and (ii) realization of higher turnover numbers through elevation of the current level of 20--10^3^ to ≥10^3^--10^4^ or higher, the ZACA reaction promises to provide a widely applicable, efficient, and selective asymmetric method for the synthesis of a variety of chiral organic compounds. In view of the abundant presence of deoxypropionate-containing natural products with diverse fascinating biological activities, intense efforts for the development of efficient and stereoselective methods for their synthesis have been made.^[@r84],[@r85])^ Since deoxypropionates are devoid of heterofunctional groups that could assist asymmetric C--C or C--H bond formation, most of the currently known and widely used methods for their constructions have to install temporary functional or chiral directing groups that are to be removed later. These methods construct deoxypropionate units in a linear-iterative fashion, and one iteration cycle typically requires 3--6 steps to introduce one methyl-branched chiral center.

Through several conceptual and methodological breakthroughs, some highly efficient, selective, and practical processes for the synthesis of deoxypropionates and related compounds containing two or more asymmetric carbon atoms have been developed in the authors' group through exploitation of the *statistical enantiomeric amplification principle* (Table [2](#tbl02){ref-type="table"}). These breakthroughs include (i) realization that Me-branched chiral compounds can be synthesized by ZACA reaction via a few alternate and mutually complementary routes (Scheme [5](#sc05){ref-type="scheme"}), (ii) unexpected finding that *2*,*4-dimethyl-1-hydroxybutyl moieties can be readily purified by ordinary chromatography* (Scheme [6](#sc06){ref-type="scheme"}),^[@r83])^ and (iii) subsequent Pd- or Cu-catalyzed cross-coupling proceeds with essentially full (\>99%) retention of newly formed chiral centers (Scheme [7](#sc07){ref-type="scheme"}).^[@r86])^

*One-Pot ZACA--Pd-Catalyzed Vinylation Tandem Process for One-Step Iterative Homologation by a Propylene Unit*. Initially, the authors' group used a three-step iterative homologation cycle for incorporation of one propylene unit,^[@r83])^ which consisted of (i) ZACA-oxidation, (ii) iodination, and (iii) metalation--Pd-catalyzed vinylation. Since the initial ZACA reaction product is an alkylalane, its direct use in the Pd-catalyzed vinylation was explored by skipping oxidation and iodination, which led to a highly efficient one-pot ZACA--Pd-catalyzed vinylation tandem process for one-step iterative homologation by a propylene unit.^[@r86])^ The isoalkyldimethylalanes, generated by ZACA reaction, was directly used for Pd-catalyzed vinylation with (i) Zn(OTf)~2~ as an additive, (ii) Pd(DPEphos)Cl~2~ and ^*i*^Bu~2~AlH (DIBAL-H) in a 1:2 molar ratio as a catalyst system, and (iii) DMF as a solvent. The ZACA reaction of 1-octene proceeded in 75% *ee* (Mosher ester analysis of 2-methyl-1-octanol after oxidation). After Pd-catalyzed vinylation at elevated temperature (even at 120 ℃), the product **7** was formed in 75% *ee*. Thus, no detectable racemization took place under the conditions of the Pd-catalyzed vinylation.

The one-pot ZACA--Pd-catalyzed vinylation tandem process developed above has been used to the synthesis of α,ω-diheterofunctional deoxypolypropionates and related compounds containing two or more asymmetric carbon atoms,^[@r86],[@r87])^ *e.g.*, all-(*R*)-2,4,6,8-tetramethyldecanoic acid, a preen gland wax of graylag goose, Anser anser (Scheme [8](#sc08){ref-type="scheme"}).^[@r87])^

Recently, we developed a highly concise, convergent, and enantioselective access to polydeoxypropionates.^[@r88])^ ZACA--Pd-catalyzed vinylation was used to prepare smaller deoxypropionate fragments, and then two key sequential Cu-catalyzed stereocontrolled sp^3^--sp^3^ cross-coupling reactions^[@r89])^ allowed convergent assembly of smaller building blocks to build-up long polydeoxypropionate chains with excellent stereoselectivity. We employed this strategy for the synthesis of phthioceranic acid, a key constituent of the cell-wall lipid of Mycobacterium tuberculosis, in just 8 longest linear steps with essentially full (\>99%) stereocontrol (Scheme [9](#sc09){ref-type="scheme"}).

ZACA--lipase-catalyzed acetylation--Pd- or Cu-catalyzed cross-coupling processes
================================================================================

Having developed unprecedentedly efficient methods for the synthesis of deoxypolypropionates with two or more stereogenic carbon centers as discussed above, it was acutely realized that, *only if ZACA products containing just one stereogenic carbon center can be readily and predictably purified*, *the ZACA-based asymmetric synthetic method would become much more widely applicable*. The senior author recently became fully aware of the following strengths and weaknesses of the previously known lipase-catalyzed (*S*)-selective acetylation: (i) Enantiomerically pure (*R*)-2-methyl-1-alkanols can be reliably obtained from their racemic mixtures, although the maximally attainable yield (or recovery) of (*R*)-alcohols of ≥98% *ee* is limited to 50% or, more specifically ≤25% if *E* = 10, ≤35% if *E* = 20, and ≤45% if *E* = 100, where *E* (enantiomeric ratio or selectivity factor) = ln\[(1 − *C*)(1 − *ee*)\]/ln\[(1 − *C*)(1 + *ee*)\] and *C* and *ee* are the extent of conversion and the enantiomeric excess of the unreacted alcohol, respectively.^[@r90],[@r91])^ As such, it is not an attractive method, especially if the starting 2-methyl-1-alkanols are very expensive; (ii) Much more striking and important is that the lipase-catalyzed acetylation method is practically incapable of providing the ≥99% pure acetates of (*S*)-2-methyl-1-alkanols from their racemic mixtures in one cycle, since it can be predicted that the maximally attainable yields of ≥99% pure acetates would be ≤1--2% (*E* ≤ 100).^[@r90],[@r91])^ Consequently, iterative purification processes, in which the purity of desired compound must be gradually elevated, will be required. This theoretical prediction also points to a significant advantage in being able to start with enantiomerically enriched (*S*)-2-methyl-1-alkanols as shown in Table [3](#tbl03){ref-type="table"}. Some maximally attainable yields of ≥99% pure acetates of (*S*)-2-methyl-1-alkanols can be predicted as follows: ≤80% if the initial *ee*~o~ is 70% and *E* is 50; ≤85% if *ee*~o~ is 80% and *E* is 30; ≤95% if *ee*~o~ is 90% and *E* is 20.^[@r90],[@r91])^ It is clear that neither the ZACA reaction alone nor the lipase-catalyzed acetylation alone is capable of providing a satisfactory method for the synthesis of either *R* or *S* isomer of 2-methyl-1-alkanols of ≥99% isomeric purity but that a combination of the two would be, provided that (i) the ZACA reaction is sufficiently enantioselective, preferably 80--90% *ee* but minimally ≥70% *ee* and (ii) the *E* values are sufficiently high, preferably ≥20--30. The ZACA--lipase-catalyzed acetylation sequential process has indeed been successfully applied to the purification of either *R* or *S* isomers of 2-methyl-1-alkanols, as represented in Table [4](#tbl04){ref-type="table"}.^[@r92])^ Thus, 2-alkyl-1-alkanols, even in some cases of lacking any proximal π-bonds or heterofunctional groups, have been efficiently synthesized in ≥98% *ee* by ZACA--lipase-catalyzed acetylation sequential protocol.^[@r92])^

As discussed above, the efficiency of the lipase-catalyzed acetylation critically depends on the selectivity factor(*E*).^[@r90],[@r91])^ In more demanding (feebly chiral) cases, especially when two alkyl groups are very similar, it is difficult to purify to \>98% *ee* even from enantiomerically enriched mixtures by lipase-catalyzed acetylation. To overcome this difficulty, the ZACA--lipase-catalyzed acetylation--Pd- or Cu-catalyzed cross-coupling sequential process was considered and developed for the synthesis of various feebly chiral 2-alkyl-1-alkanols of \>99% *ee* as outlined in Scheme [10](#sc10){ref-type="scheme"}.^[@r93])^ By virtue of the high selectivity factor(*E*) associated with iodine, either (*S*)- or (*R*)-enantiomer of 3-iodo-2-alkyl-1-alkanols (**3**), prepared by ZACA reaction of allyl alcohol, can be readily purified to the level of ≥99% *ee* by lipase-catalyzed acetylation. A variety of chiral tertiary alkyl-containing alcohols, including those that have been otherwise difficult to prepare, can now be synthesized in high enantiomeric purity by Pd- or Cu-catalyzed cross-coupling of (*S*)-**3** or (*R*)-**4** for introduction of various primary, secondary and tertiary carbon groups with retention of all carbon skeletal features.^[@r93])^

The ZACA--lipase-catalyzed acetylation--Pd- or Cu-catalyzed cross-coupling process has been applied to highly efficient and enantioselective synthesis of various chiral compounds. (*R*)-Arundic acid is currently undergoing Phase II development for the treatment of acute ischemic stroke, as well as clinical development in other neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.^[@r94],[@r95])^ (*R*)- and (*S*)-**5** of ≥99% *ee*, prepared via ZACA--lipase-catalyzed purification--Cu-catalyzed cross-coupling (Scheme [11](#sc11){ref-type="scheme"}), were transformed into the corresponding (*R*)- and (*S*)-arundic acids in 98% yield by oxidation with NaClO~2~ in the presence of catalytic amounts of NaClO and 2,2,6,6-tetramethylpiperidin-1-yloxyl (TEMPO). Thus, a highly enantioselective (≥99% *ee*) and efficient synthesis of (*R*)- and (*S*)-arundic acids was achieved in 25% and 28% over five steps, respectively, from allyl alcohol.^[@r93])^

(*S*)-2-Methyl-3-iodo-1-propanol **6** of ≥99% *ee*, obtained by ZACA-iodolysis--lipase-catalyzed acetylation from allyl alcohol, was converted to 1,1-dibromo-alkene **7** in 74% yield over four steps.^[@r87])^ Compound **7** was further transformed to **8**, a potential intermediate for the synthesis of callystatin A, by PdCl~2~(DPEphos)-catalyzed Negishi coupling reactions where the second Negishi coupling proceeding with a clean stereoinversion (Scheme [12](#sc12){ref-type="scheme"}).^[@r87])^

As satisfactory as the procedure shown in Scheme [10](#sc10){ref-type="scheme"} is, its synthetic scope is limited to the preparation of 2-chirally-substituted 1-alkanols. In search for an alternative and more generally applicable procedure, we developed a new protocol for the synthesis of γ- and more-remotely chiral alcohols of high enantiomeric purity through simple paradigm shift, as summarized in Scheme [13](#sc13){ref-type="scheme"}.^[@r96])^

Having developed a widely applicable route to various γ- and more-remotely chiral alcohols by ZACA/oxidation--lipase-catalyzed acetylation--Cu- or Pd-catalyzed cross-coupling protocol, our attention was necessarily and increasingly drawn into the methods of determination of enantiomeric purities of the final desired alcohols, which proved to be quite challenging. For most of alkanols where the stereogenic center generated was in the γ or δ position relative to the OH group, the enantiomeric purities of ≥99% *ee* were successfully determined by chiral gas chromatography or NMR analysis of Mosher esters.^[@r97])^ However, initial attempts to determine the enantiomeric excess in more demanding cases, such as 4-alkyl-1-alcohols and 5-alkyl-1-alcohols, using chiral GC, HPLC and Mosher ester analysis were unsatisfactory.

A solution to the above-mentioned difficulty was found through the use of 2-methoxy-2-(1-naphthyl)propionic acid (MαNP), which had been used in determining the absolute configuration of chiral secondary alcohols.^[@r98],[@r99])^ Presumably the naphthyl ring of MαNP esters would exert greater anisotropic shielding effects than α-methoxy-α-trifluoromethylphenylacetic acid (MTPA) phenyl group. Indeed, the two terminal methyl groups of the diastereomeric MαNP ester (*R*,*R*)- and (*R*,*S*)-**13**, derived from ε-chiral alcohol (*R*)-**11**, showed completely separate ^1^H NMR signals, while the diastereomeric MTPA ester **12** showed no separation (Scheme [14](#sc14){ref-type="scheme"}). The MαNP ester analysis was also successfully applied to chiral discrimination of other δ- and ε-chiral primary alcohols, which demonstrated surprising long-range anisotropic differential shielding effects. It should be noted that the diastereotopic chemical shift differences of MαNP esters were affected by NMR solvent and resonance frequency (MHz) of NMR. *d*-Acetonitrile, *d*-acetone, *d*-methanol and/or CDCl~3~ have been shown to be suitable solvents. The higher the resonance frequency, the better discrimination of chemical shifts obtained.

ZACA--lipase-catalyzed acetylation--Cu-catalyzed cross-coupling synergy has been applied to a highly enantioselective (\>99% ee) and diastereoselective (\>98% de) synthesis of chiral C~15~ vitamin E side-chain **19** (Scheme [15](#sc15){ref-type="scheme"}).^[@r100])^ The key α,ω-dioxyfunctional C~5~ synthon **15** (≥99% ee) was readily prepared by ZACA--lipase-catalyzed acetylation, which can be further functionalized at both ends. Two sequential Cu-catalyzed alkyl--alkyl cross-coupling reactions of the enantiomerically pure C~5~ iodide **16** were employed as the key steps for preparing the C~15~ vitamin E side-chain **19**, which was shown to be \>99% ee by ^1^H NMR analysis of its MαNP ester (Scheme [16](#sc16){ref-type="scheme"}).^[@r100])^

Chiral compounds arising from the replacement of hydrogen (H) with deuterium (D) are very important in the fields of organic chemistry and biochemistry. Some of these chiral compounds whose specific rotation values are practically non-measurable, due to very small differences between the isotopomeric groups, exhibit "cryptochirality"^[@r101]--[@r103])^ representing a class of compounds which have been very difficult to synthesize and distinguish. Our ZACA--lipase-catalyzed acetylation--Cu-catalyzed cross-coupling processes provide a general and efficient method for the highly enantioselective (≥99% *ee*) and catalytic synthesis of various 1-alkanols of isotopomeric "cryptochirality" (Scheme [17](#sc17){ref-type="scheme"}).^[@r104])^

Three deuterium-substituted δ-chiral isotopomers (*R*)-**22**, **23**, and **24** were prepared by ZACA/oxidation--lipase-catalyzed acetylation--Cu-catalyzed cross-coupling. ZACA reaction of TBS-protected 4-penten-1-ol followed by *in situ* oxidation with O~2~ provided intermediate (*S*)-**25** of 85% *ee* in 67% yield. This crude (*S*)-**25** was readily purified to the level of ≥99% *ee* by Amano PS lipase-catalyzed acetylation in 70% recovery.^[@r96])^ After conversion of (*S*)-**25** into iodide, Cu-catalyzed cross-coupling with three different deuterium-substituted Grignard reagents was then used for the synthesis of isotopomers (*R*)-**22**, **23**, and **24** (Scheme [18](#sc18){ref-type="scheme"}).^[@r104])^ To further demonstrate the high efficiency of ZACA--lipase-catalyzed acetylation tandem process for preparation of α,ω-dioxyfunctional alcohols in high enantiomeric purity, one control experiment of lipase-catalyzed acetylation of *rac*-**25** was performed. Under the optimal conditions, lipase-catalyzed acetylation of *rac*-**25** still only produced (*S*)-**25** of 87.8% *ee* in a disappointingly low recovery of 10%. Thus, it is practically impossible to synthesize (*S*)-**25** of ≥99% *ee* through lipase-catalyzed acetylation of a racemic mixture of **25**.

As might be expected, none of these isotopomers synthesized above exhibited measurable optical rotation due to very small differences between the isotopomeric groups, such as CH~3~ *vs.* CDH~2~, CH~3~CH~2~ *vs.* CD~3~CH~2~, and CH~3~CH~2~CH~2~ *vs.* CH~3~CD~2~CH~2~. Enantiomeric purities (≥99% *ee*) of β- and γ-chiral isotopomers, *e.g.*, (*S*)-**21**, were successfully determined by ^1^H NMR analysis of their Mosher esters.^[@r97])^ As shown in Scheme [19](#sc19){ref-type="scheme"}, the terminal methyl groups of the diastereomeric Mosher esters (*S*,*R*)- and (*S*,*S*)-**26**, derived from γ-chiral alkanol (*S*)-**21**, showed completely separate ^1^H NMR signals. The enantiomeric purities of more remotely chiral, *e.g.*, δ- and ε-chiral, isotopomers have been determined by the MαNP ester analysis.

Conclusions
===========

The ZACA reaction is a catalytic asymmetric C--C bond forming reaction of terminal alkenes of one-point-binding without requiring any other functional groups, even though various functional groups may be present. Through conversion of terminal alkenes to chiral alkylalanes which allow for a wide range of *in situ* transformations, ZACA reaction provides a widely applicable, efficient and selective method for catalytic asymmetric C--C bond formation, which has already been used for the syntheses of various chiral natural products as summarized in Table [5](#tbl05){ref-type="table"}. It should be noted that ZACA--lipase-catalyzed acetylation--transition metal-catalyzed cross-coupling processes provide a general and ultimately satisfactory access towards a variety of chiral organic compounds with ultra-high (\>99%) purity levels, which have been otherwise very difficult to synthesize. One of the paradigms we rely heavily on is (i) to purify functionally rich and thus readily purifiable intermediates prepared by ZACA reaction to the level of \>99% ee by lipase-catalyzed acetylation, and (ii) to further modify through the use of Pd- or Cu-catalyzed cross-coupling proceeding with essentially full (\>99%) retention of all carbon skeletal features of intermediates.
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![The synthesis of C~15~ vitamin E side-chain **19**.](pjab-91-369-g015){#sc15}

![^1^H NMR spectra of diastereomeric MαNP esters of γ-chiral alcohol **19** (CDCl~3~, 600 MHz).](pjab-91-369-g016){#sc16}

![Synthesis of various chiral isotopomers of 1-alkanols.](pjab-91-369-g017){#sc17}

![Synthesis of δ-chiral isotopomers.](pjab-91-369-g018){#sc18}

![Methyl resonances in the ^1^H NMR spectra (CD~3~CN, 600 MHz) of Mosher ester derived from γ-chiral alkanol (*S*)-**21**.](pjab-91-369-g019){#sc19}

###### 

Some representative examples of natural products synthesized by using Zr-catalyzed carboalumination of alkynes

  Year                                                                 Name of Natural Product                                  Reference
  -------------------------------------------------------------------- -------------------------------------------------------- -----------
  2005                                                                 bis-Deoxylophotoxin                                      [@r25]
  2006                                                                 *N*-Acetylcysteamine thioester of *seco*-Proansamitoci   [@r26]
  Carbazomadurin B                                                     [@r27]                                                   
  1,22-Dihydroxynitianes                                               [@r28]                                                   
  (+)-Epolactaene                                                      [@r29]                                                   
  Aurisides A and B                                                    [@r30]                                                   
  (3*S*)-Oxidosqualene (analogs)                                       [@r31]                                                   
  Dolabelide C (C1--C15 fragment)                                      [@r32]                                                   
  2007                                                                 Amphidinolide X and Y (C12--C21 fragment)                [@r33]
  Dechloroansamitocin P-3                                              [@r34]                                                   
  Iromycins                                                            [@r35]                                                   
  Nakiterpiosin                                                        [@r36]                                                   
  Coenzyme Q10                                                         [@r37]                                                   
  (−)-Reidispongiolide A                                               [@r38]                                                   
  Iridal's core structure                                              [@r39]                                                   
  (±)-Phomactin B2                                                     [@r40]                                                   
  Amphidinolide H and G                                                [@r41]                                                   
  2008                                                                 Callipeltoside Aglycone                                  [@r42]
  Bafilomycin A1 (C1--C17 and C18--C25 fragments)                      [@r43]                                                   
  Nafuredinmilbemycin β3, and (−)-bafilomycin A1 (key intermediates)   [@r44]                                                   
  (−)-Reidispongiolide A                                               [@r45]                                                   
  2009                                                                 Amphidinolides B1, B4, G1, H1, and H2                    [@r46]
  Phomactins                                                           [@r47]                                                   
  Verticipyrone                                                        [@r48]                                                   
  (+)-Myrrhanol A                                                      [@r49]                                                   
  Plaunotol                                                            [@r50]                                                   
  Marinomycin A (monomeric counterpart)                                [@r51]                                                   
  2010                                                                 Carbazomadurin A                                         [@r52]
  Meiogynin A                                                          [@r53]                                                   
  Maytansinoids                                                        [@r54]                                                   
  Ansamitocins P-2 to P-4                                              [@r54]                                                   
  2011--2015                                                           Mycolactones A and B                                     [@r55]
  Leiodermatolide (macrocyclic core)                                   [@r56]                                                   
  *N*-acetyl-S-farnesyl-L-cysteine                                     [@r57]                                                   
  FTPA triazole I                                                      [@r58]                                                   
  (+)-Concanamycin F                                                   [@r59]                                                   
  Bafilomycin A1                                                       [@r60]                                                   
  Palmerolide (C16--C24 fragment)                                      [@r61]                                                   
  Carbazomadurin A                                                     [@r62]                                                   
  (*S*)-(+)-Carbazomadurin B                                           [@r62]                                                   
  Leiodolide A (C22--C31 fragment)                                     [@r63]                                                   
  Celastrol                                                            [@r64]                                                   
  Enokipodin B                                                         [@r65]                                                   
  24-Fluorinated Bafilomycin (analog)                                  [@r66]                                                   
  Ieodomycins A and B                                                  [@r67]                                                   
  Amphidinolides C, C2, and C3 (C-18--C-34 Fragment)                   [@r68]                                                   
  Verrillin (functionalized core)                                      [@r69]                                                   
  (+)-Myrrhanol C                                                      [@r70]                                                   
  Myceliothermophins C, D, and E                                       [@r71]                                                   

###### 

Statistical enantiomeric amplification in iterative enantioselective process

  *ee* in step or species I (%)   *ee* in step or species II (%)   Overall *ee* (%)
  ------------------------------- -------------------------------- ------------------
  70                              70                               94.0
  80                              80                               97.6
  90                              80                               98.8
  90                              90                               99.4
  99                              99                               99.995

###### 

Significance of high initial enantiomeric excess (ee~o~) and selectivity factor(E) on the maximally attainable yields of (S)-2-alkyl-1-alkanols of \>98% ee^[@r90],[@r91])^

  --
  --

^a^*E* (enantiomeric ratio or selectivity factor) = ln\[(1 − *C*)(1 − *ee*)\]/ln\[(1 − *C*)(1 + *ee*)\]

*C* and *ee* are the extent of conversion and the enantiomeric excess of the unreacted alcohol, respectively

###### 

ZACA--lipase-catalyzed acetylation processes for the synthesis of 2-methyl-1-alkanols

  --
  --

###### 

Natural products and related compounds of biological and medicinal interest synthesized via ZACA reaction

  Entry    Chiral Compounds of Biological and Medicinal Interest (Year)           Structure   Total or Fragment Synthesis
  -------- ---------------------------------------------------------------------- ----------- -----------------------------------------------------------
  \(1\)    vitamin E (2001 and 2002)^[@r82],[@r105])^                                         total
  \(2\)    vitamin K (2001 and 2007)^[@r92],[@r105])^                                         total
  \(3\)    phytol (2001)^[@r105])^                                                            total
  \(4\)    scyphostatin (2004, 2010 and 2012)^[@r106]--[@r108])^                              sidechain^[@r106],[@r107])^ and total synthesis^[@r108])^
  \(5\)    TMC--151A-F C11--C20 fragment (2004)^[@r83])^                                      C11--C20 fragment
  \(6\)    siphonarienal (2004)^[@r109])^                                                     total
  \(7\)    siphonarienone (2004)^[@r109])^                                                    total
  \(8\)    siphonarienolone (2004)^[@r109])^                                                  total
  \(9\)    (+)-sambutoxcin C9--C18 fragment (2004)^[@r109])^                                  C9--C18 fragment
  \(10\)   6,7-dehydrostipiamide (2004)^[@r110])^                                             total
  \(11\)   ionomycin C1--C10 fragment (2005)^[@r86])^                                         C1--C10 fragment
  \(12\)   borrelidin C3--C11 fragment (2005)^[@r86])^                                        C3--C11 fragment
  \(13\)   preen gland wax of the graylag groose, *Anser anser* (2006)^[@r87])^               total
  \(14\)   doliculide C1--C9 fragment (2006)^[@r87])^                                         C1--C9 fragment
  \(15\)   (+)-stellattamide A (2007)^[@r92])^                                                sidechain
  \(16\)   (+)-stellattamide B (2007)^[@r92])^                                                C5--C11 sidechain
  \(17\)   (−)-spongidepsin (2007)^[@r111])^                                                  total
  \(18\)   (+)-discodermolide (2007)^[@r112])^                                                C11--C17 fragment
  \(19\)   (−)-callystatin A (2007)^[@r112])^                                                 C1--C11 fragment
  \(20\)   archazolides A and B (2007)^[@r112])^ A: R = Me B: R = H                           C7--C15 fragment
  \(21\)   nafuredin (2008)^[@r44])^                                                          C9--C18 fragment (formal total)
  \(22\)   milbemycin β~3~ (2008)^[@r44])^                                                    C1--C13 fragment
  \(23\)   bafilomycin A~1~ (2008)^[@r44])^                                                   C1--C11 fragment
  \(24\)   fluvirucinin A~1~ (2008)^[@r113])^                                                 total
  \(25\)   4,6,8,10,16,18-hexamethyldocosane (2008)^[@r114])^                                 total
  \(26\)   yellow scale pheromone (2008)^[@r115])^                                            total
  \(27\)   (*R*)- and (*S*)-arundic acids (2012)^[@r93])^                                     total
  \(28\)   phthioceranic acid (2015)^[@r88])^                                                 total
  \(29\)   (7*S*,10*R*)-pitiamide A (2000)^[@r116])^                                          total
  \(30\)   (7*R*,10*R*)-pitiamide A (2000)^[@r116])^                                          total
  \(31\)   (+)-bistramide C (2005)^[@r117])^                                                  total

[^1]: (Communicated by Ryoji NOYORI, M.J.A.)
